Auger electron radioimmunotherapeutic agent specific for the CD123 +/CD131- phenotype of the leukemia stem cell population

Journal of Nuclear Medicine

Volumn 52, Issue 9, 2011, Pages 1465-1473

  Leyton, Jeffrey Victor ^a   Hu, Meiduo ^a   Gao, Catherine ^a   Turner, Patricia V ^b   Dick, John E ^c   Minden, Mark ^c,d   Reilly, Raymond M ^a,c,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF GUELPH   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

111In; Auger electrons; Leukemia stem cells; Micro SPECT CT; Radioimmunotherapy

Indexed keywords

AUGER ELECTRON RADIOIMMUNOTHERAPEUTIC AGENT; CD123 ANTIGEN; CD131 ANTIGEN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G2; INDIUM 111; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 7G3; PENTETATE INDIUM IN 113M; RADIOPHARMACEUTICAL AGENT; T LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; BRAIN; CELL FRACTIONATION; CELL NUCLEUS; COMPUTER ASSISTED TOMOGRAPHY; DNA DAMAGE; DOUBLE STRANDED DNA BREAK; DRUG CYTOTOXICITY; DRUG TRANSPORT; FEMUR; FLOW CYTOMETRY; IMMUNOREACTIVITY; IN VITRO STUDY; LEUKEMIA; LEUKEMIA STEM CELL; LEUKOCYTE; LYMPH NODE; MOUSE; NONHUMAN; NUCLEAR TRANSLOCATION SEQUENCE; PRIORITY JOURNAL; RADIOASSAY; SIMIAN VIRUS 40; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPINE; SPLEEN; STEM CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE MARROW; CELL LINE, TUMOR; CELL NUCLEUS; CELL SURVIVAL; COORDINATION COMPLEXES; CYTOKINE RECEPTOR COMMON BETA SUBUNIT; DNA DAMAGE; ELECTRONS; IMMUNOCONJUGATES; INDIUM RADIOISOTOPES; INTERLEUKIN-3 RECEPTOR ALPHA SUBUNIT; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; PHENOTYPE; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 80052622425     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.087668     Document Type: Article

References (27)

1. Lane SW, Scadden DT, Gilliland DG. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood. 2009;114:1150-1157.
2. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730-737. (Pubitemid 27298715)
3. Ishikawa F, Yoshida S, Saito Y, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol. 2007;25:1315-1321. (Pubitemid 350076512)
4. Wulf G, Wang R-Y, Kuehnle I, et al. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood. 2001;98:1166-1173.
5. Shipley JL, Butera JN. Acute myelogenous leukemia. Exp Hematol. 2009;37:649-658.
6. Reilly RM, Kassis A. Targeted Auger electron radiotherapy of malignancies. In: Reilly RM, ed. Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer. Hoboken, NJ: John Wiley & Sons, Inc.; 2010:289-348.
7. Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14:1777-1784.
8. Sun Q, Woodcock JM, Rapoport A, et al. Monoclonal antibody 7G3 recognizes the N-terminal domain of the human interleukin-3 (IL-3) receptor α-chain and functions as a specific IL-3 receptor antagonist. Blood. 1996;87:83-92. (Pubitemid 26018391)
9. Costantini DL, Hu M, Reilly RM. Peptide motifs for insertion of radiolabeled biomolecules into cells and routing to the nucleus for cancer imaging or radiotherapeutic applications. Cancer Biother Radiopharm. 2008;23:3-24. (Pubitemid 351304218)
10. Cencic R, Carrier M, Trnkus A, Porco Jr. JA, Minden M, Pelletier J. Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in myelogenous leukemia cells. Leukemia Res. 2010;34:535-541.
11. Chen P, Wang J, Hope K, et al. Nuclear localizing sequences (NLS) promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells. J Nucl Med. 2006;47:827-836. (Pubitemid 46768447)
12. Jin L, Lee EM, Ramshaw HS, et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor a chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell. 2009;5:31-42.
13. 111In-DTPA-hEGF. J Nucl Med. 2008;49:1353-1361.
14. Michel RB, Ochakovskaya R, Mattes MJ. Rapid blood clearance of injected mouse IgG2a in SCID mice. Cancer Immunol Immunother. 2002;51:547-556. (Pubitemid 35232004)
15. Glatting G, Müller M, Koop B, et al. Anti-CD45 monoclonal antibody YAML568: a promising radioimmunoconjugate for targeted therapy of acute leukemia. J Nucl Med. 2006;47:1335-1341. (Pubitemid 47544889)
16. Burke JM, Caron PC, Papadopolous EB, et al. Cytoreduction with iodine-131- anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone Marrow Transplant. 2003;32:549-556. (Pubitemid 37185088)
17. Kotzerke J, Glatting G, Seitz U, et al. Radioimmunotherapy for the intensification of conditioning before stem cell transplantation: differences in dosimetry and biokinetics of 188Re- and 99mTc-labeled anti-NCA-95 Mabs. J Nucl Med. 2000;41:531-537. (Pubitemid 30133975)
18. Roberts AW, He S, Bradstock KF, et al. A phase 1 and correlative biological study of CSL360 (anti-CD123 mAb) in AML. Paper presented at: Proceedings of the 50th Annual Meeting American Society of Hematology; December 6-9, 2008; San Francisco, CA.
19. 111In-anti-CD33 monoclonal antibodies modified with nuclear localizaing peptide sequences. J Nucl Med. 2008;49:1546-1554.
20. Du X, Ho M, Pastan I. New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells. J Immunother. 2007;30:607-613. (Pubitemid 47229695)
21. Wängler C, Moldenhauer G, Eisenhut M, Haberkorn U, Mier W. Antibody-dendrimer conjugates: the number, not the size of the dendrimers, determines the immunoreactivity. Bioconjug Chem. 2008;19:813-820. (Pubitemid 351614537)
22. McCormack E, Bruserud O, Gjertsen BT. Animal models of acute myelogenous leukemia: development, application and future perspectives. Leukemia. 2005;19:687-706. (Pubitemid 40663086)
23. Agliano A, Martin-Padura I, Mancuso P, et al. Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rγ null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. Int J Cancer. 2008;123:2222-2227.
24. Ailles LE, Gerhard B, Kawagoe H, Hogge DE. Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice. Blood. 1999;94:1761-1772. (Pubitemid 29411327)
25. Bonnet D, Bhatia M, Wang JYC, Kapp U, Dick JE. Cytokine treatment or accessory cells are required to initiate engraftment of purified primitive human hematopoietic cells transplanted at limiting doses into NOD/SCID mice. Bone Marrow Transplant. 1999;23:203-209. (Pubitemid 29078332)
26. Pearce DJ, Taussig D, Zibara K, et al. AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood. 2006;107:1166-1173. (Pubitemid 43156319)
27. Taussig DC, Pearce DJ, Simpson C, et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood. 2005;106:4086-4092. (Pubitemid 41775913)